Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 22;128(12):1562-6.
doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen  1 , Ajay K Gopal  2 , Scott E Smith  3 , Stephen M Ansell  4 , Joseph D Rosenblatt  5 , Kerry J Savage  6 , Joseph M Connors  6 , Andreas Engert  7 , Emily K Larsen  8 , Dirk Huebner  9 , Abraham Fong  8 , Anas Younes  10
Affiliations

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen et al. Blood. .

Abstract

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of 5-year follow-up results. OS and PFS were analyzed using Kaplan-Meier methodology and are shown (A-B) overall and (C-D) by best response. All censored patients are indicated by dots on the Kaplan-Meier curve. Patients followed through study closure and in remission without the start of new therapy other than allo-SCT are indicated by red dots (N = 15). (E) Observation time for the subset of 15 patients still in remission and in follow-up at study closure. Patients are shaded according to their best response with brentuximab vedotin. Six patients received a consolidative allo-SCT, and 9 patients received no further therapy after completing brentuximab vedotin. (F-G) OS and PFS are shown for the patients who achieved a CR on brentuximab vedotin (N = 34) as the subset of patients who received a consolidative allo-SCT (N = 6) or did not (N = 28). All censored patients are indicated by dots on the Kaplan-Meier curve.
See this image and copyright information in PMC

Comment in

References

    1. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540–10547. - PubMed
    1. Oflazoglu E, Stone IJ, Gordon KA, et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood. 2007;110(13):4370–4372. - PubMed
    1. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in Mycosis Fungoides and Sezary Syndrome with variable CD30 expression level: A multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758. - PMC - PubMed
    1. Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741–755. - PubMed
    1. Gardai SJ, Epp A, Law C-L. Brentuximab vedotin-mediated immunogenic cell death [abstract]. Cancer Res. 2015 75(15 Suppl). Abstract 2469.

Associated data